PMID- 40983036
OWN - NLM
STAT- Publisher
LR  - 20250922
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
DP  - 2025 Sep 22
TI  - Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple 
      myeloma in the TRIMM-2 study.
LID - blood.2025029360 [pii]
LID - 10.1182/blood.2025029360 [doi]
AB  - Talquetamab, a GPRC5D-targeting bispecific antibody for relapsed/refractory 
      multiple myeloma (RRMM), plus daratumumab may lead to deeper and more durable 
      responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with 
      RRMM (at least 3 prior lines of therapy or double refractory to a proteasome 
      inhibitor and an immunomodulatory drug) received subcutaneous talquetamab 0.4 
      mg/kg weekly (QW; "QW cohort") or 0.8 mg/kg every other week (Q2W; "Q2W cohort") 
      plus daratumumab 1800 mg per the approved schedule. The primary end point was 
      safety. Secondary end points included overall response and duration of response. 
      Progression-free survival was an exploratory end point. Sixty-five patients 
      (median 5 prior lines of therapy; 61.5% triple-class refractory; 24.6% bispecific 
      antibody-exposed) received talquetamab plus daratumumab (QW, n = 14; Q2W, n = 51; 
      median follow-up: 18.6 months). Most common adverse events were oral events, skin 
      events, cytokine release syndrome, and infections. Grade 3/4 events occurred in 
      81.5%. Two patients had dose-limiting toxicities, both in the Q2W cohort (grade 3 
      stomatitis/oral mucositis and grade 3 maculopapular rash). Responses occurred in 
      71.4% (QW cohort) and 82.4% (Q2W cohort) of patients. Median progression-free 
      survival was 23.3 and 21.2 months, respectively, in each cohort. Pharmacodynamic 
      results suggest the immunomodulatory action of daratumumab contributes to a 
      conducive environment for talquetamab by reducing immunosuppressive cells. 
      Talquetamab plus daratumumab demonstrated promising efficacy outcomes in heavily 
      pretreated patients, with a safety profile consistent with each agent as 
      monotherapy. ClinicalTrials.gov ID: NCT04108195.
CI  - Copyright © 2025 American Society of Hematology.
FAU - Chari, Ajai
AU  - Chari A
AD  - Univeristy of California, San Francisco, San Francisco, California, United 
      States.
FAU - van de Donk, Niels W C J
AU  - van de Donk NWCJ
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
FAU - Dholaria, Bhagirathbhai
AU  - Dholaria B
AUID- ORCID: 0000-0003-2371-3655
AD  - Vanderbilt University Medical Center, Nashville, Tennessee, United States.
FAU - Weisel, Katja C
AU  - Weisel KC
AD  - University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Mateos, Maria-Victoria
AU  - Mateos MV
AUID- ORCID: 0000-0003-2390-1218
AD  - Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de 
      Salamanca, Instituto de Biologia Molecular y Celular del Cancer (Universidad de 
      Salamanca-Consejo Superior de Investigacion, Salamanca, Spain.
FAU - Goldschmidt, Hartmut
AU  - Goldschmidt H
AUID- ORCID: 0000-0003-0961-0035
AD  - Universitätsklinikum Heidelberg, Med. Klinik V, GMMG-Studygroup, Heidelberg, 
      Germany.
FAU - Martin, Tom G
AU  - Martin TG
AUID- ORCID: 0000-0002-9133-9813
AD  - UCSF, San Francisco, California, United States.
FAU - Morillo, Daniel
AU  - Morillo D
AD  - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
FAU - Reece, Donna
AU  - Reece D
AD  - Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
FAU - Rodriguez-Otero, Paula
AU  - Rodriguez-Otero P
AUID- ORCID: 0000-0001-5236-7785
AD  - Cancer Center Clínica Universidad de Navarra, Pamplona, Spain.
FAU - Bhutani, Manisha
AU  - Bhutani M
AUID- ORCID: 0000-0002-9019-7438
AD  - Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States.
FAU - D'Souza, Anita
AU  - D'Souza A
AD  - Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
FAU - Oriol, Albert
AU  - Oriol A
AUID- ORCID: 0000-0001-6804-2221
AD  - ICO - Hosp Germans Trias i Pujol, Badalona, Spain.
FAU - Rosiñol, Laura
AU  - Rosiñol L
AUID- ORCID: 0000-0002-2534-9239
AD  - Hospital Clínic, IDIBAPS, Barcelona, Spain.
FAU - Bahlis, Nizar J
AU  - Bahlis NJ
AUID- ORCID: 0000-0001-7353-7034
AD  - Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, 
      Canada.
FAU - Vishwamitra, Deeksha
AU  - Vishwamitra D
AD  - Johnson & Johnson, United States.
FAU - Skerget, Sheri
AU  - Skerget S
AD  - Johnson & Jphnson, United States.
FAU - Verona, Raluca I
AU  - Verona RI
AUID- ORCID: 0000-0003-0044-4341
AD  - Johnson & Johnson, United States.
FAU - Bakshi, Kalpana K
AU  - Bakshi KK
AD  - Johnson & Johnson, Spring House, Pennsylvania, United States.
FAU - Kang, Lijuan
AU  - Kang L
AD  - Johnson & Johnson, Spring House, Pennsylvania, United States.
FAU - Prior, Thomas J
AU  - Prior TJ
AUID- ORCID: 0000-0001-5220-7730
AD  - Johnson & Johnson, United States.
FAU - Vandenberk, Lien
AU  - Vandenberk L
AD  - Johnson & Johnson, Beerse, Belgium.
FAU - Tolbert, Jaszianne
AU  - Tolbert J
AD  - Johnson & Johnson, Raritan, New Jersey, United States.
FAU - Lee, Sangmin
AU  - Lee S
AD  - Johnson & Johnson, Spring House, Pennsylvania, United States.
FAU - Smit, Damiette
AU  - Smit D
AD  - Enliven Therapeutics, Boulder, Colorado, United States.
FAU - Wäsch, Ralph
AU  - Wäsch R
AUID- ORCID: 0000-0002-0813-3444
AD  - University Medical Center, Freiburg, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT04108195
PT  - Journal Article
DEP - 20250922
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
EDAT- 2025/09/22 18:38
MHDA- 2025/09/22 18:38
CRDT- 2025/09/22 18:02
PHST- 2025/08/13 00:00 [accepted]
PHST- 2025/04/01 00:00 [received]
PHST- 2025/07/28 00:00 [revised]
PHST- 2025/09/22 18:38 [medline]
PHST- 2025/09/22 18:38 [pubmed]
PHST- 2025/09/22 18:02 [entrez]
AID - 547408 [pii]
AID - 10.1182/blood.2025029360 [doi]
PST - aheadofprint
SO  - Blood. 2025 Sep 22:blood.2025029360. doi: 10.1182/blood.2025029360.
